Clinical and laboratory status in Parkinson’s disease patients with and without polyneuropathy
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 81 (10) , 613-618
Abstract
Background/Aim. The etiology of polyneuropathy (PNP) in patients with Parkinson?s disease (PD) is unclear, and there is a possible association between levodopa therapy, hyperhomocysteinemia, and PNP development due to methylation processes involving vitamin B12 and folic acid. The aim of this study was to analyze the difference in clinical presentation and disease severity between PD patients with and without PNP and to evaluate blood levels of vitamin B12, homocysteine, and folic acid in these patients. Methods. This cross-sectional study included 200 consecutive patients diagnosed with PD, divided into two groups: those with PNP and those without PNP. Diagnosis of PNP was confirmed by electromyoneurography. The first group consisted of 50 patients with PD with confirmed PNP, and the second 50 patients with PD without PNP. All patients were receiving levodopa therapy. Laboratory tests analyzed vitamin B12, folic acid, and homocysteine levels. Results. Patients with PNP were older when PNP was diagnosed (71 vs. 66 years, p < 0.0001), without differences in duration of levodopa therapy (p = 0.359) or daily dose (p = 0.442), and with significant motor impairment according to Unified Parkinson?s Disease Rating Scale III (p = 0.017). No difference was found between groups for vitamin B12 (p = 1.0), folic acid (p = 0.124), and homocysteine (p = 0.313) serum levels. Conclusion. PD patients with PNP have a more pronounced motor deficit, while differences in vitamin B12, homocysteine, and folic acid values compared to the group without PNP were not registered.Keywords
This publication has 34 references indexed in Scilit:
- Correlates of polyneuropathy in Parkinson’s diseaseAnnals of Clinical and Translational Neurology, 2020
- Validation study of the hoehn and yahr scale included in the MDS‐UPDRSMovement Disorders, 2018
- Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathyBrain and Behavior, 2017
- Somatosensory symptoms in unmedicated de novo patients with idiopathic Parkinson’s diseaseJournal of Neural Transmission, 2015
- Cutaneous neuropathy in Parkinson’s disease: a window into brain pathologyActa Neuropathologica, 2014
- Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter studyMovement Disorders, 2013
- Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson diseaseAnnals of Neurology, 2010
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Neuropathy as a potential complication of levodopa use in Parkinson's diseaseMovement Disorders, 2008
- Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's diseaseMovement Disorders, 2004